Modified cell expansion and uses thereof
First Claim
Patent Images
1. A method for enhancing T cell expansion in a subject having cancer, the method comprising:
- obtaining modified T cells comprising a chimeric antigen receptor (CAR) binding tMUC comprising an amino acid sequence of SEQ ID NO;
70 and a CAR binding CD19 comprising an amino acid sequence of SEQ ID NO;
5 or 6, wherein the CAR comprises an antigen binding domain, a transmembrane domain, and a cytoplasmic domain and wherein the modified T cells comprise autologous T cells derived from the subject; and
administering an effective amount of the modified T cells to the subject, wherein the modified T cells enhance the expansion of the modified T cells in the subject as compared to the subject administered with modified T cells comprising the CAR binding CD19 in the absence of CAR binding tMUC or administered with modified T cells comprising the CAR binding tMUC in the absence of CAR binding CD19.
2 Assignments
0 Petitions
Accused Products
Abstract
The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion in vivo and/or in vitro. For example, a cell may comprise a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR may recognize a surface molecule of a blood cell.
-
Citations
9 Claims
-
1. A method for enhancing T cell expansion in a subject having cancer, the method comprising:
-
obtaining modified T cells comprising a chimeric antigen receptor (CAR) binding tMUC comprising an amino acid sequence of SEQ ID NO;
70 and a CAR binding CD19 comprising an amino acid sequence of SEQ ID NO;
5 or 6, wherein the CAR comprises an antigen binding domain, a transmembrane domain, and a cytoplasmic domain and wherein the modified T cells comprise autologous T cells derived from the subject; andadministering an effective amount of the modified T cells to the subject, wherein the modified T cells enhance the expansion of the modified T cells in the subject as compared to the subject administered with modified T cells comprising the CAR binding CD19 in the absence of CAR binding tMUC or administered with modified T cells comprising the CAR binding tMUC in the absence of CAR binding CD19. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
Specification